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Abstract
Background: It has been shown previously that administration of Francisella tularensis (Ft) Live Vaccine Strain (LVS)
lipopolysaccharide (LPS) protects mice against subsequent challenge with Ft LVS and blunts the pro-inflammatory
cytokine response.
Methods: To further investigate the molecular mechanisms that underlie Ft LVS LPS-mediated protection, we
profiled global hepatic gene expression following Ft LVS LPS or saline pre-treatment and subsequent Ft LVS
challenge using Affymetrix arrays.
Results: A large number of genes (> 3,000) were differentially expressed at 48 hours post-infection. The degree of
modulation of inflammatory genes by infection was clearly attenuated by pre-treatment with Ft LVS LPS in the
surviving mice. However, Ft LVS LPS alone had a subtle effect on the gene expression profile of the uninfected
mice. By employing gene set enrichment analysis, we discovered significant up-regulation of the fatty acid
metabolism pathway, which is regulated by peroxisome proliferator activated receptors (PPARs).
Conclusions: We hypothesize that the LPS-induced blunting of pro-inflammatory response in mouse is, in part,
mediated by PPARs (a and g).
Background
Tularemia is caused by the Gram-negative, non-motile,
intracellular coccobacillus, Francisella tularensis (Ft),s o
named after Tulare county of California where the dis-
ease was initially identified [1]. Rodents, along with rab-
bits and hares, are the chief hosts of the bacterium. It is
transmitted to humans mostly by insect bites, handling
of animal carcasses, and ingestion or inhalation. Symp-
toms of tularemia typically appear 3 to 5 days after
initial contact with the pathogen and include sudden
fever, chills, headaches, diarrhea, muscle aches, joint
pain, dry cough and progressive weakness; however, the
symptoms and the severity of illness, are highly depen-
d e n tu p o nt h ed o s ea n dr o u t eo fi n o c u l a t i o n[ 2 ] .T h e
number of cases of tularemia has steadily declined in
the United States since 1950; between 1990 and 2000,
only 1,368 cases of tularemia were reported to the Cen-
ters for Disease Control and Prevention (CDC) with an
annual average of approximately 120 cases until 2003
[3]. The CDC has classified Ft as a Category A agent
due to its low infectious dose, easy dissemination by the
aerosol route, and potential to cause severe morbidity
and mortality. Ft has been used previously as a biologi-
cal weapon [4]. Furthermore, during the cold war, both
the United States and the former Soviet Union stock-
piled Ft for use as a potential biological weapon [2,5].
An attenuated “Live Vaccine Strain” (LVS), developed
in the former Soviet Union by repeated passage of Ft
subspecies holarctica on agar plates and subsequently
through mice [6], has been used to vaccinate humans.
While vaccination with Ft LVS provides significant pro-
tection against more highly virulent strains [7-9], the
strain has not been licensed for general public use in
the United States due to the fact that the molecular
basis for the attenuation is presently unknown [10].
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and causes an infection that resembles human tularemia
[11].
Infection of mice with Ft results in a marked inflam-
matory response that has been suggested to be responsi-
b l ef o rm o s to ft h et i s s u ed a m a g ea s s o c i a t e dw i t h
human tularemia [11,12]. Mice challenged i.p. with Ft
LVS display the highest bacterial burden in the liver
when compared to spleen and lung [13]. Interaction of
Ft with cells of the innate immune system (macro-
phages, dendritic cells, neutrophils, NK cells) initiates a
cascade of cytokine production including IFN-g,T N F - a
leading to production of reactive nitrogen and oxygen
species [14]. In the liver, increased bacterial burden is
accompanied by increased hepatic mRNA synthesis of
the pro-inflammatory genes TNF-a,I F N - g,K C ,M C P - 1 ,
and iNOS. A later wave of gene expression is associated
with the development of “alternatively activated” macro-
phages that facilitates increased intracellular replication
of Ft and, ultimately, death [15].
LPS, an integral structural component of the outer
membrane of all Gram-negative bacteria, is often a pri-
mary mediator of host inflammatory sequelae induced
by Gram-negative bacterial infection. Unlike enterobac-
terial LPS, previous studies have shown that Ft LVS LPS
is weakly endotoxic and a poor Toll-like receptor (TLR)
4 agonist [16]. Despite its lack of endotoxic properties,
mice pre-treated with Ft LVS LPS two days prior to
lethal Ft LVS challenge are protected and display
decreased bacterial burden as well as a reduced inflam-
matory response [13]. This previous work assessed
changes in gene expression using real-time PCR and,
therefore, a relatively small subset of inflammatory
genes was analyzed. To gain insights into the mechan-
ism(s) of Ft LPS-mediated protection of mice from
death caused by Ft LVS, we profiled hepatic transcrip-
tome (using Affymetrix expression arrays) of Ft-infected
mice with or without LPS-pre-treatment.
Methods
Sample preparation
Female C57BL/6J mice were obtained from Jackson Labs
in Bar Harbor, ME. 48 hours prior to Ft LVS challenge,
mice were injected i.p. with either 100 ng of Ft LVS LPS
or an equivalent volume of saline. On the day of chal-
lenge, 3 saline- and 3 Ft LVS LPS-pre-treated animals
were sacrificed (uninfected controls), while all remaining
mice were challenged i.p. with ~4-5 × 10
5 Ft LVS. Ft
LVS-challenged mice were sacrificed (in groups of 3) at
24 and 48 hours post-infection. This entire experiment
was performed 3 times. Within each individual experi-
ment, equal amounts of extracted RNA from biological
replicate samples were pooled. Pooled RNA from sepa-
rate experiments was used as biological replicates. All
experimental procedures were approved by the Institu-
tional Animal Care and Use Committee and met or
exceeded requirements of the Public Health Service/
National Institutes of Health and the Animal Welfare
Act.
RNA extraction
Whole liver was collected from mice and preserved in
RNAlater® (Applied Biosystems/Ambion Foster City,
CA). After homogenization, total RNA was extracted
and purified using the RNAeasy system according to
manufacturer’s instructions (Qiagen Valencia, CA). The
QIAGEN RNase-free DNase supplement kit was used to
ensure that the RNA was free from DNA contamination.
All RNA samples were checked for both quality and
quantity as described previously [17,18].
Real Time PCR
Real-time PCR was performed in a Sequence Detector
System (ABI Prism 7900 Sequence Detection System
and software; Applied Biosystems, Foster City, CA) as
described previously [19]. Levels of mRNA for specific
murine genes were reported as relative gene expression
over background levels detected in control samples. Pri-
mers were designed using the Primer Express™ Program
(Applied Biosystems, Foster City, CA) in conjunction
with GenBank with the following sequences.
B-cell leukemia/lymphoma 6 forward: GTCAGAGT
ATTCGGATTCTAGCTGTG
B-cell leukemia/lymphoma 6 reverse: GCAGCGT
GTGCCTCTTGAG
Traf 2 binding protein (TIFA) forward: GGCCACTG
GAAGACTCTCAGG
Traf 2 binding protein (TIFA) reverse: GGATGGTAA
ATGGTCATCTGGAG
cytochrome P450, family 2, subfamily b, polypeptide
10 (Cyp2b10) forward: CAGACACCATAAGGGAG
GCTCT
cytochrome P450, family 2, subfamily b, polypeptide
10 (Cyp2b10) reverse: GATCACACCATATTCCTTG
AAGGTT
Heat shock protein 1B (Hspa1b) forward: GCACG
GCGTGTGAGAGG
Heat shock protein 1B (Hspa1b) reverse: TGATG
GATGTGTAGAAGTCGATGC.
GeneChip hybridization
RNA was processed and labelled according to the stan-
dard target labelling protocols and the samples were
hybridized, stained, and scanned per standard Affyme-
trix protocols at VBI core laboratory on Mouse 430 2.0
expression arrays (Affymetrix Inc., Santa Clara, CA).
This platform consists of 45,101 probe sets representing
21,309 genes of the mouse genome.
Microarray data analysis
Data input and subsequent steps were performed using
the Bioconductor package “affy” [20] in R statistical
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obtained from CEL files were pre-processed by the
gcRMA algorithm (GC Robust Multiarray Average) [22]
that performs the three steps: (i) adjustment of the gene
expression signal against the background caused by opti-
cal noise and non-specific binding, (ii) robust multi-
array normalization [23], and (iii) summarization of the
probes belonging to each probe set.
The probe sets were further selected in an unbiased
manner by removing those associated with a very low
degree of variability (inter-quartile range less than 0.5)
across all the samples. This reduced the number of
probe sets from 45,101 to 19,535. Statistical analysis
was performed using the software package “limma”
[24] by applying a linear model to the expression mea-
surement (log intensities) for each gene. For each com-
parison of interest, the genes were assigned p-values
after controlling for false discovery rate [25]. For
assessment of differential expression, the empirical
Bayes method was applied [26]. A cut-off of p < 0.05
and > = 2-fold change was used as the criterion for
w h e t h e ro rn o tag e n ew a ss i g n i f i c a n t l ym o d u l a t e db y
a treatment. All the significantly modulated genes in
any of the pair wise comparison of interest are listed
in Additional file 1. The microarray data (both raw
and normalized) have been submitted at the Gene
Expression Omnibus (GEO, http://www.ncbi.nlm.nih.
gov/geo/, Data set: GSE16207).
Gene set enrichment analysis (GSEA)
All pathways listed at KEGG [27-29] were selected for
analysis. The degree of differential regulation of a path-
way was derived from the collective differential regula-
tion of the member genes in that pathway, as described
below. Each pathway was assigned a score (ZK)b yc o m -
bining individual t-statistic of the genes in that pathway,
using the following formula [30]:
Pathway score 
Sum of individual gene-level   statistics
N

 t
u umber of genes in the pathway
where the t-statistic is a measure of the individual
differential expression for each gene in the pathway.
While each individual t-statistic represents the gene-
level difference between two groups (treated versus
control), the pathway score represents the pathway-
level difference between the two groups. Calculation of
the pathway score was performed using the bioconduc-
tor package GSEABase [31]. GSEA has earlier been
shown to detect differential regulation of pathways
when gene-level changes are very small or undetectable
[32,33] and hence was considered appropriate for the
present context. The pathway observed to be most sig-
nificantly modulated was confirmed by permutation
testing with the gseattperm function in the package
Category [34]. The pathway scores are listed in Addi-
tional file 2.
Comparison of differential gene expression due to LPS
treatment
In view of the regulatory role of peroxisome prolifera-
tor-activated receptors (PPARs) in fatty acid metabolism,
the gene expression of three PPAR isoforms (PPARa,
PPARg, PPARb/δ) were subjected to further analysis.
Our goal was to detect if post-infection gene expression
of PPAR was consistently elevated by LPS pre-treatment.
Hence a t-test (paired by time-point) between two con-
ditions (LPS and No LPS) was performed for each iso-
form, as described below. For each time point
(uninfected, 24 hr PI and 48 hr PI), differences between
the two treatments were calculated as d0,d 1 and d2
respectively, using the formulas below.
dL P S N o L P S
dL P S N o L P S
d
Uninfcted Uninfected
hrPI hrPI
0
12 4 2 4
2


 L LPS NoLPS hrPI hrPI 48 48 
Each of the values d0, d1, and d2 refers to the differ-
ence of the average gene expression of 3 samples. The
average and variation of these numbers were compared
against a normal distribution and tested if the mean was
significantly different from zero. For PPARa and g (but
not b/δ), the effect was found to be statistically signifi-
cant (p < 0.05).
Comparison of differential gene expressions due to LPS
treatment and infection on fatty acid metabolism
A similar method as described above was applied to
assess the effect of infection and LPS treatment on fatty
acid metabolism. In this case, our intention was to com-
pare the average direction of change in the expression
of a total of 24 genes involved in fatty acid metabolism
after challenging the mice with LPS alone (48 hours) or
infection alone (24 hours). The time point of 24 hours
post-infection was chosen to detect the early changes
post-infection. For each gene, differences of gene
expression due to LPS (Dp) and due to infection (Di)
were calculated as follows:
Dp LPS NoLPS
Di NoLPS NoLPS
Uninfcted Uninfected
hrPI Uninfec

 24 t ted
For each gene, it refers to the difference of the gene
expression values averaged over 3 samples. The average
and variation of these numbers (Dp and Di) were com-
pared against a normal distribution and tested if the
mean was significantly different from zero. For each
case (LPS or infection), the average differences of Dp
and Di were tested against normal distribution found to
be significantly different from zero (p < 0.01).
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Alteration in gene expression after infection
We discovered 3,515 genes to be differentially expressed
after 48 hours of infection. These include Bcl proteins 3,
6, and 10; heat shock proteins 1, 1A, 1B, and 90; genes
induced by interferons; interleukin 1b; and LPS binding
protein and tumor necrosis factor. For easier data visua-
l i z a t i o n ,as h o r t e rl i s to f7 9o ft h e s eg e n e s( w i t h> 4 0 -
fold change) is presented in the heat map in Additional
file 3 A. Genes with modified expression fell into two
categories based on whether they were up or down-
regulated by infection. The up-regulated genes include
interferon g (IFN-g) as well as chemokine (C-X-C motif)
ligands IP-10 (Cxcl10), KC (Cxcl1), and MCP-1 (Ccl2).
This is consistent with our previously published results
on up-regulation of pro-inflammatory cytokines by
mouse liver upon Ft LVS infection [13]. The genes that
were down-regulated at 48 hours post-infection include
carbonic anhydrase 3 and guanidinoacetate methyltrans-
ferase, both of which are known to be down-regulated
in response to liver injury [35,36].
The time course for gene expression for up- and down-
regulated genes was examined separately. Box plots were
drawn for each group of genes across the three time
points: uninfected, 24 hours, and 48 hours post-infection
(Additional file 3B, C). For each post-infection time point,
saline- and LPS-pre-treatedm i c ew e r ej u x t a p o s e d .T w o
trends are visible in these box plots. First, with time, infec-
tion progressively alters the level of gene expression (red-
colored boxes). This is true for both up- and down-regu-
lated genes. Secondly, LPS-pre-treatment (green boxes)
opposes the transcriptional changes caused by Ft LVS
infection at both 24 hours and 48 hours post-infection,
thus keeping the gene expression level less deviated from
uninfected state. Effect of LPS-pre-treatment was found to
be statistically significant (p < 0.01) for both up- and
down-regulated genes.
We discovered a total of 34 genes to be differentially
e x p r e s s e dc o m p a r e dt ou n i n f e c t e dc o n t r o l .T h e s e
included chemokine ligand IP-10 and genes controlled
by pro-inflammatory cytokines TNF-a,I L - 1 b,I F N - g;
namely, interferon regulatory factor 1, Cd274 antigen,
metallothionein 2, proteasome subunit (Psmb9), and
tumor necrosis factor Tnfsf10 were progressively up-
regulated after infection. Similar to the trend seen for
the other group, up-regulation of these genes at 24
hours post-infection was lessened by LPS-pre-treatment.
In addition to the effects on the specific genes, LPS-
pre-treatment had a substantial influence on the number
of genes differentially expressed due to infection. A total
of 3,515 genes were found to be differentially expressed
in mice without LPS-pre-treatment, but only 1,494
genes with LPS-pre-treatment after 48 hours post-
infection as compared to the uninfected controls (0 hr
post-infection). For more than 99% of the latter list of
genes (1,483 out of 1,494) the N-fold was in the same
direction as that in mice without LPS-pre-treatment.
Furthermore, for 1,100 of these 1,483 genes, the magni-
tude of change was smaller in the LPS pre-treated mice,
suggesting LPS had a general blunting effect on infec-
tion-induced gene expression profile.
Validation of select genes
Validation of the data from a selected number of genes
was carried out by quantitative real-time RT-PCR
(qRTPCR). Relative gene expression of four genes (Bcl6,
Traf2 binding protein, heat shock protein 1B, and Cyto-
chrome P450) was measured by qRTPCR. These genes
were found to have similar trends as seen on the micro-
arrays (Fig. 1). Another set of genes (TNF-a,I L - 1 b,I L -
6, IFN-g, IP-10, KC, MCP-1, RANTES) reported earlier
to be up-regulated [13] were also examined. Both micro-
array and qRTPCR measurements for these genes were
consistent with respect to the direction of change at a
statistically significant level (Fig. 2).
LPS-induced changes in pathways
While LPS-pre-treatment blunted up-regulation of genes
at 24 and 48 hours post-infection, no significant changes
in gene expression could be demonstrated in the livers
of mice that received LPS and were sacrificed prior to
Ft challenge (i.e., 48 hours after LPS injection). This
finding suggests that the earliest transcriptional changes
were subtle or that the initial modulation of the host
response to Ft occurred in an extra-hepatic location. In
order to enhance the discriminatory power of the small
changes at the level of individual gene expression, we
employed a GSEA analytic strategy that relies on coordi-
nated expression of functionally related genes. We first
compared saline- and LPS-treated mice at time point
zero, which is equivalent to measuring the effect on glo-
bal gene expression profile after 48 hours of LPS treat-
ment. Pathway scores were calculated between the two
conditions. The most up-regulated pathway “Fatty acid
metabolism” (KEGG ID: 00071) was found to be statisti-
cally significant from permutation testing (Fig. 3). Many
of the genes in this pathway are transcriptionally regu-
lated by PPARs.
PPARs belong to the superfamily of nuclear hormone
receptors with three known isoforms, a,b or δ,a n dg,
that differ in their tissue distribution and functional
activity [37]. While PPARb/δ is ubiquitous, PPARg is
expressed in adipocytes, T- and B-cells, monocytes/
macrophages, dendritic cells, and epithelial cells [38,39].
However, it is PPARa that is reported to be highly
expressed in liver cells [40]. We found that, under all
conditions and at all time-points, the level of PPARa
gene expression is highest in the liver followed by
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noid X receptor (RXRa) that binds to DNA on PPAR
response elements and controls the expression of a
number of genes participating in metabolism. The gene-
products regulated by PPARa participate in a number
of metabolic processes including cellular fatty acid
uptake, intracellular fatty acid transport, ketogenesis,
lipoprotein metabolism, microsomal fatty acid ω-oxida-
tion, mitochondrial fatty acid b-oxidation, mitochondrial
fatty acid uptake, peroxisomal fatty acid b-oxidation,
and peroxisomal fatty acid uptake [41]. As shown in the
right column of Fig. 5, PPARa, g, and most of the genes
participating in fatty acid metabolism are expressed at a
higher level (red) after LPS treatment (fold change > 1)
as compared to the uninfected and untreated (No LPS)
control. On the contrary, most of the same genes
expressed at a lower level (green) after infection (fold
change < 1) as compared to the uninfected and
untreated (No LPS) control. The averages of these fold
changes across all the genes in the fatty acid metabolism
was significantly (p < 0.01) higher due to LPS treatment
and lower due to infection.
Figure 1 Real-time PCR of 4 genes. Measurement of relative gene expression in infected mice (with respect to uninfected mice without LPS-
pre-treatment) of four different genes by two different methods. The top row corresponds to microarray while the bottom row corresponds to
quantitative real-time PCR. In each plot, the red line corresponds to the group of mice with LPS-pre-treatment, the black line, without LPS.
Horizontal axis corresponds to the days after infection, vertical axis to relative gene expression. Gene expression trends are similar between the
two methods of measurement.
Figure 2 Agreement with previously published result.
Agreement of microarray data with gene expression changes
measured by quantitative real-time PCR (qRTPCR) [13]. In both
studies the mice were pre-treated with either 100 ng of Ft LVS LPS
or equivalent volume of saline (Untreated) 48 hours before infection
and sacrificed at 48 hours post-infection. Each number represents
the fold-increase in the mRNA levels after infection. While there was
rise in the pro-inflammatory cytokine levels post-infection, LPS
caused a reduction in expression of these genes (comparable
between qRTPCR and microarray; Spearman correlation at p <
0.001).
Figure 3 List of significant pathways. List of pathways found to
be significantly up-regulated by permutation testing of the KEGG
pathways. The pathway Fatty acid metabolism (KEGG ID: 00071) was
found to have the highest pathway score (Additional file 2). Many
genes participating in fatty acid metabolism are regulated by PPARs.
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Ft LVS infection of mice is associated with profound
changes in the levels of pro-inflammatory cytokines
whose expression is decreased by pre-treatment with
100 ng of Ft LVS LPS. After 48 hours post-infection,
LPS-treated mice exhibit significantly reduced hepatic
gene expression [13] (Fig. 2), circulating cytokine levels
[13] and increased survival [13]. We previously postu-
lated that pre-treating the mice with LPS accomplishes
the following results: (i) dampened bacterial growth, (ii)
suppressed pro-inflammatory response, and (iii) induc-
tion of a late Ag-specific protective adaptive immune
response [13]. It was recently shown that the latter is
due to the induction of Ft LVS LPS-specific antibodies
by a subset of B1a cells [42]. Upon global profiling of
h e p a t i cg e n ee x p r e s s i o n ,w ed i s c o v e r e dan u m b e ro f
genes that were differentially expressed, especially at 48
hours post-infection, a time at which many of these
changes were counteracted by prior LPS treatment. The
effect of LPS treatment was less evident at 24 hours
post-infection or at day 0 (without infection). Since it is
clear that LPS protects the mice from death by Ft LVS,
we made the reasonable assumption that the protective
molecular changes were already in motion 48 hours
after LPS treatment (day 0) and we sought to discover
the gene expression signature of those LPS-induced
changes. Using “G e n es e te n r i c h m e n ta n a l y s i s ” that
explores coordinated changes in functionally related
genes, we discovered that the KEGG pathway “Fatty
acid metabolism” was up-regulated at 48 hours post-
infection. Further investigation pointed to simultaneous
up-regulation of PPARa and g by LPS-pre-treatment
(Fig. 5).
Many of the genes in the “Fatty acid metabolism”
pathway are transcriptionally controlled by peroxisome
proliferator-activated receptors (PPARs). PPARs (a, b/δ
and g) are master regulators of energy homeostasis.
They are nuclear receptors that upon activation by spe-
cific ligands bind to specific response elements near the
promoter of their target genes. In this way, PPARs sense
the lipid concentration and composition in the cellular
environment [43,44]. In fact, PPARs are the receptors
for endogenous lipid molecules such as prostaglandins
or hydroxy-containing PUFA such as 12/15-
Figure 4 Expression of PPAR genes in mouse liver. Hepatic gene expression levels of three different peroxisome proliferator-activated
receptor genes. Gene expression level was calculated from normalized intensities for six groups of samples. Error bars correspond to standard
deviation among the three biological replicates. PPARa is the most highly expressed of the three genes (followed by PPARg). Furthermore, effect
of LPS treatment was assessed for each gene by using a paired t-test (please see details in subsection “Comparison of specific gene expression”
under Methods section). The asterisk indicates that LPS treatment causes significant up-regulation (p < 0.05) of PPARa and PPARg, but not
PPARb/δ.
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dienoic (HODE), and dietary compounds such as conju-
gated linoleic acid. PPARa and g were originally
identified as the molecular target for the fibrate class of
lipid-lowering drugs or the thiazolidinedione (TZD)
class of antidiabetic drugs, respectively. Our results
show that the down-regulation of the proinflammatory
cytokine and chemokine response induced by LPS pre-
treatment is paralleled by increased expression of
PPARa and g. In the liver, PPARa is mainly expressed
by hepatocytes, where it regulates oxidation of free fatty
acids. Its ligands include unsaturated fatty acids and
eicosanoids derived from arachidonic and linoleic acids.
We show that LPS-pre-treatment resulted in up-regula-
tion of the enzymes involved in fatty acid oxidation (Fig.
5), which suggests a higher degree of PPARa activation
by endogenous ligands.
Both PPARa and g are expressed in Kupffer cells, a
specialized subset of macrophages that reside in the
hepatic sinusoids [45]. Other immune cells present in
the liver such as dendritic cells or T cells also express
PPARg[46]. In addition to its role in lipid metabolism,
PPARa and g have long been recognized for their influ-
ence on inflammatory pathways [47] mostly by repres-
sion of pro-inflammatory gene expression. More
recently, it has been shown that liver PPARa controls
Figure 5 Modulation of genes belonging to fatty acid metabolism by LPS and infection. Heat map showing the effect of infection and
LPS on transcription of genes participating in fatty acid metabolism, including the genes PPARa and g. The three columns correspond to the
effect of Ft LVS infection alone (24 and 48 hour post-infection) and LPS alone (48 hour post-LPS). The treated group (post-infection or post-LPS)
was compared with the untreated control for calculation of fold change (numbers inside the cells). The green color suggests down-regulation
(fold change < 1); red color up-regulation (fold change > 1). Genes regulated by PPARa and g belong to multiple pathways including cellular
fatty acid uptake, intracellular fatty acid transport, ketogenesis, lipoprotein metabolism, microsomal fatty acid ω-oxidation, mitochondrial fatty
acid b-oxidation, mitochondrial fatty acid uptake, peroxisomal fatty acid b-oxidation, and peroxisomal fatty acid uptake [41]. Most genes
(participating in fatty acid metabolism) are up-regulated after LPS treatment (red color of the cells in the right column) but are down-regulated
after infection (green color in the left column). Both post-infection and post-LPS changes in expression of this set of genes were observed to be
statistically significant as detected by paired t-test between treated and control groups (p < 0.01; please see details in subsection “Comparison of
specific gene expression” under Methods section).
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tion of pro-inflammatory cytokine gene expression [48].
In this model, PPARa modulates both TNF-a/IL-1 and
IL-6 signaling through a direct action on the pathway or
via the down-regulation of IL-1-mediated stimulation of
IL-6 expression. This model is consistent with our find-
ing of up-regulated PPARa-responsive genes and
reduced levels of pro-inflammatory cytokine gene
expression and protein levels. Interestingly, while puri-
fied Ft LPS causes an up-regulation of PPARs and their
responsive genes, infection with the whole bacterium
causes down-regulation of the same genes (Fig. 5).
These findings are in line with a recent report demon-
strating that E. coli LPS up-regulated PPARg expression
in the immune system of pigs by inducing the genera-
tion of endogenous PPARg agonists such as 15d PGJ (2)
[49]. Thus, while enterobacterial and Ft LPS differ in
molecular targets (i.e., TLR4 versus TLR2, respectively)
and their ability to induce inflammatory cytokines, both
types of LPS may induce the generation of endogenous
PPAR agonists as a mechanism of down-regulating
inflammation.
PPARg has been recently shown to be a key molecular
switch in the induction of alternatively activated macro-
phages [50]. Moreover, it has been shown that infection of
macrophages with Ft LVS induced alternative activation
with up-regulation of the signature genes arginase I,
FIZZI, and macrophage mannose receptor [15]. Interest-
ingly, the cytokines IL-4 and IL-13 drive differentiation
into alternatively activated macrophages through IL-4Ra
and STAT6 signaling, [51] and in addition, IL-4 treatment
of macrophages up-regulates PPARg and PPARg respon-
sive genes [52]. While alternatively activated macrophages
display an anti-inflammatory phenotype, which might
dampen Ft LVS-induced inflammation, they are unable to
kill intracellular pathogens. In this regard, Ft LVS induced
alternatively activated macrophages through production of
IL-4 and IL-13, which resulted in enhanced intracellular
bacterial survival and replication. On the other hand, the
inability of macrophages to become alternatively activated
in IL-4Ra or STAT6-deficient mice leads to a more pro-
longed IL-12 response when compared to WT littermates
[15]. Thus, the role of PPARg in the immunopathogenesis
of tularemia should be interpreted with caution as it might
have both beneficial and detrimental effects in the out-
come of the disease. The induction of the PPAR-con-
trolled pathway in our data is consistent with
transcriptional profiling results of F. tularensis infection of
human peripheral blood mononuclear cells (PBMC) [53].
Conclusions
In summary, we have examined the gene expression of
the mouse liver before and after infection with Ft LVS,
with or without LPS-pre-treatment, and demonstrated
that, in accordance with previous results from our
laboratory, LPS causes significant attenuation of gene-
expression changes after infection with Ft LVS. Addi-
tionally, we demonstrate for the first time that Ft LPS
causes subtle changes in hepatic gene expression after
48 hours of treatment in uninfected mice. By using gene
s e te n r i c h m e n ta n a l y s i s( G S E A )w es h o w e dt h a tm a n y
genes involved in fatty acid metabolism are up-regulated
in a coordinated manner along with up-regulation of the
nuclear factor PPARa (and to a lesser extent PPARg).
We suggest that LPS-induced attenuation of pro-inflam-
matory response to Ft LVS is partly mediated through
hepatic PPARa and g, possibly through the induction of
alternatively activated macrophages. These findings are
in line with numerous reports on the anti-inflammatory
efficacy of PPARs. Future studies aimed at examining
the effect of Ft LVS or type A strains on the hepatic
and pulmonary pathology following cell-specific deletion
of PPARa or g from immune cells are needed to further
dissect the role of PPARs in the pathogenesis and pre-
vention of tularemia.
Additional file 1: Genes showing significant modulation after 48
hours of infection. All the significantly modulated genes in any of the
pair wise comparison of interest (contrasts) are listed. There are seven
contrasts: LPS_d0_Vs_Sal_d0, LPS_d1_Vs_Sal_d1 LPS_d2_Vs_Sal_d2
Sal_d1_Vs_Sal_d0, Sal_d2_Vs_Sal_d0, LPS_d1_Vs_LPS_d0
LPS_d2_Vs_LPS_d0. For each, fold change and p-values are provided.
Additionally, selection columns include 1 for significant differential
expression and 0 for no significant differential expression.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-2334-10-
10-S1.XLS]
Additional file 2: Pathway score for the KEGG pathways. Pathway
score was calculated from the gene-level fold-change in expression
induced after 48 hours of LPS treatment. Fatty acid metabolism appears
at the top of the list.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-2334-10-
10-S2.XLS]
Additional file 3: LPS lessens the impact of Ft LVS infection on
mouse liver. Gene expression changes induced by Ft LVS infection and
protection by LPS pre-treatment. (A) Heat map showing gene expression
before (Uninfected) and after infection (48 hours PI). Higher degree of
gene expression is displayed as a darker cell. This is a set of selected
genes showing maximal difference (absolute fold change of 40 or
higher) between the two groups of mice. The genes are either up- or
down-regulated by infection. Some of the genes associated with
inflammation or liver injury have been outlined: up-regulated in red
rectangle; down-regulated in green rectangle. The highlighted genes
have already been reported to be altered in response to Ft infection or
liver injury. (B) Distribution of expression signal of genes up-regulated by
infection. Each box plot corresponds to distribution of the up-regulated
genes before or after infection (24 hours, 48 hours PI). The red color
corresponds to mice without LPS pre-treatment. The green color
corresponds to mice with LPS pre-treatment. (C) Same as B, but for
down-regulated genes. In both B and C, infection causes progressive
alteration of transcription for these genes and LPS pre-treatment
opposes this trend.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-2334-10-
10-S3.PDF]
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